Emcure Pharma IPO will open for subscription from 03 July 2024. The company aims for an issue size of ₹1,952.03 Cr through this IPO.
Company Overview
Full name | Emcure Pharmaceuticals Limited |
Sector | Healthcare |
Industry | Pharmaceuticals & Drugs |
Company Website | https://www.emcure.com/ |
About Company
Emcure Pharmaceuticals stands as a prominent Indian pharmaceutical entity, dedicated to the advancement, production, and global promotion of an extensive array of pharmaceutical products spanning various critical therapeutic domains. Functioning as a research and development (R&D) oriented enterprise, Emcure boasts a distinct product portfolio encompassing oral medications, injectables, and biotherapeutics. This diverse range has facilitated its market penetration into over 70 countries, establishing a robust presence in India, Europe, and Canada.
The company has been ranked 13th in domestic sales among pharmaceutical companies in India for MAT FY 2024 and 4th in market share in its covered markets for the same period. Additionally, it is the leading pharmaceutical company in gynecology and HIV antiviral therapeutic areas for the MAT FY 2024. As of 31 March 2024, the company had a team of 548 qualified scientists and five dedicated R&D facilities in India. In addition, as of the same date, Emcure Pharmaceuticals had been granted 220 patents had 30 pending patent applications in several countries, and had submitted 102 drug master files (DMFs) for APIs with the U.S. Food and Drug Administration (USFDA).
Emcure Pharmaceuticals has 13 manufacturing facilities across India. The company has witnessed substantial sales expansion in India over the recent years. Its sales in India accounted for 48.28% of the total revenue from operations during FY 2024.
The Objectives of the Issue
- Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by the company; and
- General corporate purposes
Emcure Pharma IPO Timetable
IPO Opening date | 03 July 2024 |
IPO Closing | 05 July 2024 |
Basis of Allotment | 08 July 2024 |
Initiation Refund | 09 July 2024 |
Credit to Demat Account | 09 July 2024 |
Listing Date | 10 July 2024 |
Emcure Pharma IPO details
Issue type | Book Built Issue IPO |
IPO issue size | ₹1,952.03 Cr – 19,365,346 shares |
Fresh Issue | ₹800 Cr – 7,936,507 shares |
Offer for sale | ₹1,152.03 Cr – 11,428,839 shares |
Face value | ₹10 per share |
Price Band | ₹960 to ₹1008 per share |
Lot size | 14 Shares |
Employee Discount | ₹90 per share |
Shareholding pre-issue | 180,852,116 |
Shareholding post-issue | 188,788,623 |
Listing Exchange | BSE & NSE |
Emcure Pharma IPO Lot Size
Application | Lots | Shares | Amount |
---|---|---|---|
Retail (Min) | 1 | 14 | ₹14,112 |
Retail (Max) | 14 | 196 | ₹197,568 |
S-HNI (Min) | 15 | 210 | ₹211,680 |
S-HNI (Max) | 70 | 980 | ₹987,840 |
B-HNI (Min) | 71 | 994 | ₹1,001,952 |
Emcure Pharma Offer Documents
Emcure Pharma IPO Reservation Details
Investor Category | Shares Offered | Maximum Allottees |
---|---|---|
Anchor Investor Shares Offered | 5,779,850 (29.67%) | NA |
QIB Shares Offered | 3,853,234 (19.78%) | NA |
NII (HNI) Shares Offered | 2,889,926 (14.83%) | |
bNII > ₹10L | 1,926,618 (9.89%) | 9,174 |
sNII < ₹10L | 963,309 (4.94%) | 4,587 |
Retail Shares Offered | 6,743,160 (34.61%) | 481,654 |
Employee Shares Offered | 108,900 (0.56%) | NA |
Total Shares Offered | 19,483,388 (100%) |
Emcure Pharma Financial Performance
FY 2022 | FY 2023 | FY 2024 | |
Revenue | 5,855.39 | 5,985.81 | 6,658.25 |
Expenses | 4,946.31 | 5,278.36 | 5,978.08 |
Net income | 702.56 | 561.85 | 527.58 |
Margin (%) | 12.00 | 9.39 | 7.92 |
Emcure Pharma Valuations & Margins
FY 2022 | FY 2023 | FY 2024 (Pre Issue) | FY 2024 (Post-Issue)* | |
EPS | 36.55 | 29.36 | 27.49 | 26.34 |
PE Ratio | – | – | 34.92 – 36.66 | 36.44 – 38.26 |
FY 2022 | FY 2023 | FY 2024 | |
RONW (%) | 33.32 | 21.27 | 16.87 |
NAV | 109.69 | 138.03 | 162.93 |
ROCE (%) | 29.69 | 22.01 | 19.37 |
EBITDA (%) | 23.54 | 20.24 | 19.01 |
Debt/Equity | 0.99 | 0.83 | 0.67 |
Company Promoters
- Satish Mehta
- Sunil Mehta
Promoter Holding
Pre Issue Share Holding | 98.90% |
Post Issue Share Holding | 78.24% |
Emcure Pharma IPO GMP Update
Date | Day-wise IPO GMP | Kostak | Subject to Sauda |
9 July 2024 | 360 | – | 3,900 |
8 July 2024 | 365 | – | 4,100 |
6 July 2024 | 355 | – | 3,900 |
5 July 2024 | 320 | – | 3,500 |
4 July 2024 | 310 | – | 3,500 |
3 July 2024 | 282 | – | 3,300 |
2 July 2024 | 275 | – | 3,200 |
1 July 2024 | 260 | – | 2,900 |
29 June 2024 | 250 | – | 3,000 |
Comparison With Listed Peers
Company | PE ratio | EPS | RONW (%) | NAV | Revenue (Cr.) |
Emcure Pharmaceuticals | 36.66 | 27.49 | 16.87 | 162.93 | 6,658.25 |
Dr. Reddy’s Laboratories | 17.93 | 334.59 | 19.74 | 1,693.75 | 28,011.10 |
Cipla Limited | 30.10 | 51.01 | 15.43 | 330.78 | 25,774.09 |
Alkem Laboratories | 33.86 | 150.19 | 17.41 | 862.46 | 12,667.58 |
Torrent Pharmaceuticals | 57.74 | 48.94 | 24.15 | 202.57 | 10,728.0 |
Mankind Pharma | 45.30 | 47.68 | 20.43 | 233.73 | 10,334.78 |
Abbott India | 47.43 | 565.28 | 32.48 | 1,740.71 | 5,848.91 |
J. B. Chemicals & Pharmaceuticals | 50.49 | 35.66 | 18.90 | 188.37 | 3,484.18 |
Emcure Pharma IPO Subscription Update
Category | Subscription (times) |
---|---|
QIB | 191.24 |
NII | 49.32 |
bNII (bids above ₹10L) | 54.90 |
sNII (bids below ₹10L) | 38.16 |
Retail | 7.36 |
Employee | 8.81 |
Total | 67.87 |
Emcure Pharma IPO Allotment Status
Emcure Pharma IPO allotment status will be available on Link Intime’s website. Click on Link Intime IPO weblink to get allotment status.
Emcure Pharma IPO Listing Details
Listing Date | 10 July 2024 |
BSE Scrip Code | 544210 |
NSE Symbol | EMCURE |
ISIN | INE168P01015 |
Final Issue Price | ₹1008 per share |
Emcure Pharma IPO Listing Day Update
Listing Exchange | BSE | NSE |
Final Issue Price | ₹1,008.00 | ₹1,008.00 |
Open | ₹1,325.05 | ₹1,325.05 |
Low | ₹1,325.05 | ₹1,325.05 |
High | ₹1,384.00 | ₹1,385.00 |
Last Trade | ₹1,358.85 | ₹1,359.15 |
Emcure Pharma IPO Lead Manager(s)
- Kotak Mahindra Capital Company Limited
- Axis Capital Limited
- J.P. Morgan India Private Limited
- Jefferies India Private Limited
Emcure Pharma Registrar
Link Intime India Private Limited
C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg,
Vikhroli (West), Mumbai 400 083, Maharashtra, India
Phone: +91 810 811 4949
Email: emcure.ipo@linkintime.co.in
Website: www.linkintime.co.in
Emcure Pharma Contact Details
EMCURE PHARMACEUTICALS LIMITED
Plot No. P-1 and P-2, IT-BT Park, Phase II,
M.I.D.C., Hinjawadi, Pune 411 057, Maharashtra
Phone: +91 20 3507 0033, +91 20 3507 0000
Email: investors@emcure.com
Website: www.emcure.com
Emcure Pharma IPO FAQs
How many shares in Emcure Pharma IPO are reserved for HNIs and retail investors?
The investors’ portion for QIB – 50%, NII – 15%, and Retail – 35%.
How to apply in Emcure Public Offer?
The best way to apply in Emcure public offer is through Internet banking ASBA (know all about ASBA here). You can also apply online through your stock broker using UPI. If you prefer to make paper applications, fill up an offline IPO form and deposit the same to your broker.
What is Emcure Pharma IPO GMP today?
Emcure Pharma IPO GMP today is ₹ 360 per share.
What is Emcure IPO kostak rate today?
Emcure IPO kostak rate today is NA per application.
What is Emcure Pharma Subject to Sauda rate today?
Emcure Pharma Subject to Sauda rate today is ₹ 3,900 per application.
Final thoughts
Emcure Pharma IPO is going to hit Dalal Street soon. applying for an IPO is purely a personal choice. Study the company well and subscribe if you feel good about it. I hope this post will give you enough details to research the company fundamentally. learn well and make wise decisions.
Happy Investing